ProfileGDS4814 / ILMN_1846444
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 44% 44% 57% 13% 45% 27% 19% 31% 6% 40% 52% 14% 39% 24% 59% 33% 30% 38% 15% 25% 28% 52% 27% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)48.827144
GSM780708Untreated after 4 days (C2_1)48.652444
GSM780709Untreated after 4 days (C3_1)53.385157
GSM780719Untreated after 4 days (C1_2)41.881713
GSM780720Untreated after 4 days (C2_2)48.860345
GSM780721Untreated after 4 days (C3_2)44.933127
GSM780710Trastuzumab treated after 4 days (T1_1)43.365119
GSM780711Trastuzumab treated after 4 days (T2_1)45.799731
GSM780712Trastuzumab treated after 4 days (T3_1)39.71766
GSM780722Trastuzumab treated after 4 days (T1_2)47.759140
GSM780723Trastuzumab treated after 4 days (T2_2)51.180852
GSM780724Trastuzumab treated after 4 days (T3_2)42.329914
GSM780713Pertuzumab treated after 4 days (P1_1)47.429839
GSM780714Pertuzumab treated after 4 days (P2_1)44.308124
GSM780715Pertuzumab treated after 4 days (P3_1)54.820459
GSM780725Pertuzumab treated after 4 days (P1_2)46.278833
GSM780726Pertuzumab treated after 4 days (P2_2)45.534230
GSM780727Pertuzumab treated after 4 days (P3_2)47.205538
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)42.406115
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)44.549525
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)45.229628
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)51.06652
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)44.964427